RAVULIZUMAB
ravulizumab 300 mg/3 mL injection, 3 mL vial
RAVULIZUMAB (12884D)
12884D
Manner of administration:Injection
Restriction
Indication: Paroxysmal nocturnal haemoglobinuria (PNH)
Treatment phase: Grandfather (transition from non-PBS-subsidised treatment)
Restriction
Indication: Paroxysmal nocturnal haemoglobinuria (PNH)
Treatment phase: First Continuing Treatment
Restriction
Indication: Paroxysmal nocturnal haemoglobinuria (PNH)
Treatment phase: Subsequent Continuing Treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 2 | DPMQ: $6,574.12 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Ultomiris | |||||